Evaluation of in vitro and in vivo Efficacy of a Novel Amphotericin B-Loaded Nanostructured Lipid Carrier in the Treatment of Leishmania braziliensis Infection

References

• World Health Organization. Leishmaniasis. Leishmaniasis; Published 2020 Available from: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis. Accessed 513, 2020.
   Google Scholar
• Ramírez JL, Guevara P. Persistent infections by Leishmania (Viannia) braziliensis. Mem Inst Oswaldo Cruz. 1997;92(3):333–338. doi:10.1590/S0074-027619970003000069332597
   PubMed Web of Science ®Google Scholar
• Boaventura VS, Cafe V, Costa J, et al. Short report: concomitant early mucosal and cutaneous leishmaniasis in Brazil. Am J Trop Med Hyg. 2006;75(2):267–269. doi:10.4269/ajtmh.2006.75.26716896130
   PubMed Web of Science ®Google Scholar
• De LEB, Porto C, Da MJOC, Sampaio RNR. Tratamento da Leishmaniose Tegumentar Americana *. An Bras Dermatol. 2007;82(2):111–124. doi:10.1590/S0365-05962007000200002
   Google Scholar
• Romero GAS, De Farias Guerra MV, Paes MG, De Oliveira Macêdo V. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: therapeutic response to meglumine antimoniate. Am J Trop Med Hyg. 2001;65(5):456–465. doi:10.4269/ajtmh.2001.65.45611716098
   PubMed Web of Science ®Google Scholar
• Almeida RP, Brito J, Machado PL, et al. Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. Am J Trop Med Hyg. 2005;73(1):79–81. doi:10.4269/ajtmh.2005.73.7916014838
   PubMed Web of Science ®Google Scholar
• Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in peru. Clin Infect Dis. 2008;46(2):223–231. doi:10.1086/52404218171254
   PubMed Web of Science ®Google Scholar
• Ponte-Sucre A, Gamarro F, Dujardin JC, et al. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis. 2017;11(12):1–24. doi:10.1371/journal.pntd.0006052
   Web of Science ®Google Scholar
• Silva SC, Guimarães LH, Silva JA, et al. Molecular epidemiology and in vitro evidence suggest that Leishmania braziliensis strain helps determine antimony response among American tegumenary leishmaniasis patients. Acta Trop. 2018;178:34–39. doi:10.1016/j.actatropica.2017.10.01029042262
   PubMed Web of Science ®Google Scholar
• Taslimi Y, Zahedifard F, Rafati S. Leishmaniasis and various immunotherapeutic approaches. Parasitology. 2016;145(4):497–507. doi:doi:10.1017/S003118201600216X27974063
   PubMed Web of Science ®Google Scholar
• Cohen B. Amphotericin B toxicity and lethality: a tale of two channels. Int J Pharm. 1998;162(12):95–106. doi:doi:10.1016/s0378-5173(97)00417-1
   Google Scholar
• Bekersky I, Fielding RM, Buell D, Lawrence I. Lipid-based amphotericin B formulations: from animals to man. Pharm Sci Technol Today. 1999;2(6):230–236. doi:10.1016/S1461-5347(99)00160-110366838
   PubMedGoogle Scholar
• Ministério da Saúde B. Orientações para uso racional do medicamento anfotericina B lipossomal; Published 2014 Available from: https://www.saude.gov.br/artigos/955-saude-de-a-a-z/leishmaniose-visceral/14190-orientacoes-para-uso-racional-do-medicamento-anfotericina-b-lipossomal. Accessed 929, 2020.
   Google Scholar
• Saupe A, et al. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) – structural investigations on two different carrier systems. Biomed Mater Eng. 2005;15(5):393–402.16179760
   PubMed Web of Science ®Google Scholar
• Pardeshi C, Rajput P, Belgamwar V, et al. Solid lipid based nanocarriers: an overview. Acta Pharm. 2012;62(4):433–472. doi:10.2478/v10007-012-0040-z23333884
   PubMed Web of Science ®Google Scholar
• Tadini MC, de Freitas Pinheiro AM, Carrão DB, et al. Assessments of nanostructured lipid carriers loaded with amphotericin b: a proposal for increased stability and safety for infectious diseases. J Pharm Biomed Anal. 2017;145:576–585. doi:10.1016/j.jpba.2017.06.03428777969
   PubMed Web of Science ®Google Scholar
• de Carvalho RF, Ribeiro IF, Miranda-Vilela AL, et al. Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice. Exp Parasitol. 2013;135(2):217–222. doi:10.1016/j.exppara.2013.07.00823891944
   PubMed Web of Science ®Google Scholar
• Palma E, Pasqua A, Gagliardi A, Britti D, Fresta M, Cosco D. Antileishmanial activity of amphotericin B-loaded-PLGA nanoparticles: an overview. Materials. 2018;11(7):1167. doi:10.3390/ma11071167
   PubMed Web of Science ®Google Scholar
• Lanza JS, Pomel S, Loiseau PM, Frézard F. Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases. Expert Opin Drug Deliv. 2019;16(10):1063–1079. doi:10.1080/17425247.2019.165924331433678
   PubMed Web of Science ®Google Scholar
• Abu Ammar A, Nasereddin A, Ereqat S, et al. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis. Drug Deliv Transl Res. 2019;9(1):76–84. doi:10.1007/s13346-018-00603-030484256
   PubMed Web of Science ®Google Scholar
• Gasco MR. Method for producing solid lipid microspheres having a narrow size distribution. Inventor: Maria R. Gasco. US5250236. Filled: Aug. 2, 1991. Date of Patent: Oct. 5, 1993.
   Google Scholar
• Petersen ALDOA, Campos TA, Santos Dantas DAD, et al. Encapsulation of the HSP-90 chaperone inhibitor 17-AAG in stable liposome allow increasing the therapeutic index as assessed, in vitro, on Leishmania (L) amazonensis amastigotes-hosted in mouse CBA macrophages. Front Cell Infect Microbiol. 2018;8(AUG):1–14. doi:10.3389/fcimb.2018.0030329404279
   PubMedGoogle Scholar
• European Medicines AE. Guideline on Bioanalytical Method Validation Guideline on Bioanalytical Method Validation Table of Contents. 44 United Kingdom, 2011;1–23.
   Google Scholar
• Brasil MDS. Manual De VigilâNcia Da Leishmaniose Tegumentar. 2017.
   Google Scholar
• Sharma R, Silveira-Mattos PS, Ferreira VC, et al. Generation and characterization of a dual-reporter transgenic leishmania braziliensis line expressing eGFP and luciferase. Front Cell Infect Microbiol. 2020;9(January):1–10. doi:10.3389/fcimb.2019.00468
   Google Scholar
• De Moura TR, Novais FO, Oliveira F, et al. Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by leishmania braziliensis. Infect Immun. 2005;73(9):5827–5834. doi:10.1128/IAI.73.9.582716113301
   PubMed Web of Science ®Google Scholar
• Celes FS, Trovatti E, Khouri R, et al. DETC-based bacterial cellulose bio- curatives for topical treatment of cutaneous leishmaniasis. Sci Rep 2016;6:38330. doi:10.1038/srep38330
   Google Scholar
• Titus RG, Marchand M, Boon TLJ. A limiting dilution assay for quantifying Leishmania major in tissues of infected mice. Parasite Immunol. 1985;7(5):545–555. doi:10.1111/j.1365-3024.1985.tb00098.x3877902
   PubMed Web of Science ®Google Scholar
• Ambisome. [homepage on the Internet]. Paraná: consulta Remédios; Published 2020 Available from: https://consultaremedios.com.br/ambisome/p. Accessed 73, 2020.
   Google Scholar
• Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech.2011;12(1):13–15. doi:10.1208/s12249-010-9563-0
   Google Scholar
• Khosa A, Reddi S, Saha RN. Biomedicine & pharmacotherapy nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother. 2018;103(April):598–613. doi:10.1016/j.biopha.2018.04.05529677547
   PubMedGoogle Scholar
• Khan AA, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomed. 2013;8:2733–2744. doi:10.2147/IJN.S41521
   PubMed Web of Science ®Google Scholar
• Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. Physico-chemical stability of colloidal lipid particles. Biomaterials. 2003;24(23):4283–4300. doi:10.1016/S0142-9612(03)00331-412853260
   PubMed Web of Science ®Google Scholar
• Antoine JC, Prima E, Jouanne C, Bongrand P. Parasitophorous vacuoles of Leishmania amzonensis infected macrophages maintain an acidic pH. Infect Immun. 1990;58((3)(3)):779–787. doi:10.1128/IAI.58.3.779-787.19901689700
   PubMed Web of Science ®Google Scholar
• Hanson LH, Stevens DA. Comparison of antifungal activity of amphotericin B deoxycholate suspension with that of amphotericin B cholesteryl sulfate colloidal dispersion. Antimicrob Agents Chemother. 1992;36(2):486–488. doi:10.1128/AAC.36.2.4861605618
   PubMed Web of Science ®Google Scholar
• Johnson EM, Ojwang JO, Szekely A, Wallace TL, Warnock DW, Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations. Antimicrob Agents Chemother. 1998;42(6):1412–1416. doi:10.1128/AAC.42.6.14129624486
   PubMed Web of Science ®Google Scholar
• Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11(6):272–279. doi:10.1016/S0966-842X(03)00117-312823944
   PubMed Web of Science ®Google Scholar
• Matsumori N, Tahara K, Yamamoto H, et al. Direct interaction between amphotericin B and ergosterol in lipid bilayers as revealed by 2H NMR spectroscopy. J Am Chem Soc. 2009;131(33):11855–11860. doi:10.1021/ja903347319645473
   PubMed Web of Science ®Google Scholar
• Bruni N, Stella B, Giraudo L, Della Pepa C, Gastaldi D, Dosio F. Nanostructured delivery systems with improved leishmanicidal activity: A critical review. Int J Nanomed. 2017;12:5289–5311. doi:10.2147/IJN.S140363
   PubMed Web of Science ®Google Scholar
• Gale EF. The release of potassium ions from Candida albicans in the presence of polyene antibiotics. J Gen Microbiol. 1974;80(2):451–465. doi:10.1099/00221287-80-2-4514596987
   PubMedGoogle Scholar
• Sen YT, Ou KL, Peng PW, et al. Quantifying membrane permeability of amphotericin B ion channels in single living cells. Biochim Biophys Acta - Biomembr. 2013;1828(8):1794–1801. doi:10.1016/j.bbamem.2013.03.021
   Web of Science ®Google Scholar
• Sokol-Anderson ML, Brajtburg J, Medoff G. Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis. 1986;154(1):76–83. doi:10.1093/infdis/154.1.763519792
   PubMed Web of Science ®Google Scholar
• Mesa-arango AC, Scorzoni L, Zaragoza O. It only takes one to do many jobs: amphotericin B as antifungal and immunomodulatory drug. Front Immunol. 2012;3:1–10. doi:10.3389/fmicb.2012.0028622679445
   PubMedGoogle Scholar
• Mesa-Arango AC, Trevijano-Contador N, Román E, et al. The production of reactive oxygen species is a universal action mechanism of amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug. Antimicrob Agents Chemother. 2014;58(11):6627–6638. doi:10.1128/AAC.03570-1425155595
   PubMed Web of Science ®Google Scholar
• Gigliotti F, Shenep JL, Lott LTD. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B. Send to J Infect Dis. 1987;156(5):784–789. doi:10.1093/infdis/156.5.784
   PubMed Web of Science ®Google Scholar
• John KS, Chia Edward J, Manus M. In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin b preparations. Antimicrob Agents Chemother. 1990;34(5):906–908. doi:10.1128/AAC.34.5.9062360827
   PubMed Web of Science ®Google Scholar
• Arning M, Kliche K, Wehmeier A. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses. 1995;465:459–465. doi:10.1111/j.1439-0507.1995.tb00020.x
   Google Scholar
• Sau K, Mambula SS, Latz E, Henneke P, Golenbock DT, Levitz SM. The antifungal drug amphotericin b promotes inflammatory cytokine release by a toll-like receptor- and CD14-dependent mechanism *. J Biol Chem. 2003;278(39):37561–37568. doi:10.1074/jbc.M306137200
   Google Scholar
• Majumder N, Ganguly S, Ghosh AK, Kundu S, Banerjee A, Saha S. Chlorogenic acid acts upon Leishmania donovani arresting cell cycle and modulating cytokines and nitric oxide in vitro. Parasite Immunol. 2020;42(6):1–12. doi:10.1111/pim.12719
   Web of Science ®Google Scholar
• Ries F, Alflen A, Lopez PA, et al. Antifungal drugs influence neutrophil effector functions. Antimicrob Agents Chemother. 2019;63(6):1–17. doi:10.1128/AAC.02409-18
   Web of Science ®Google Scholar
• Kawabe K, Takano K, Moriyama M, Nakamura Y. Amphotericin B increases transglutaminase 2 expression associated with upregulation of endocytotic activity in mouse microglial cell line BV-2. Neurochem Res. 2017;42(5):1488–1495. doi:10.1007/s11064-017-2205-028224343
   PubMed Web of Science ®Google Scholar
• Rogers PD, Kramer RE, Chapman SW, Cleary JD. Amphotericin B – induced interleukin-1 b expression in human monocytic cells is calcium and calmodulin dependent. J Infect Dis. 1999;180(May):1259–1266. doi:10.1086/31500410479156
   PubMedGoogle Scholar
• Khouri R, Novais F, Santana G, et al. DETC induces Leishmania parasite killing in human invitro and murine in vivo models: A promising therapeutic alternative in leishmaniasis. PLoS One. 2010;5(12):8–9. doi:10.1371/journal.pone.0014394
   Web of Science ®Google Scholar
• Santos DM, Petersen ALOA, Celes FS, Borges VM, Veras PST, de Oliveira CI. Chemotherapeutic potential of 17-AAG against cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis. PLoS Negl Trop Dis. 2014;8(10):e3275. doi:10.1371/journal.pntd.000327525340794
   PubMed Web of Science ®Google Scholar
• Falcão SC, De MTR, Clarêncio J, Brodskyn C, Barral A, De OCI. The presence of Tregs does not preclude immunity to reinfection with Leishmania braziliensis. Int J Parasitol 2012;42:771–780. doi:10.1016/j.ijpara.2012.05.006
   Google Scholar
• Belkaid Y, Piccirillo CA, Mendez S. CD4 1 CD25 1 regulatory T cells control Leishmania major persistence and immunity. Nature 2002;420(6915):520–527. doi:10.1038/nature01199.1.
   Google Scholar